# Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

> **NCT01342484** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** placebo
- **DRUG:** BI1356 low dose
- **DRUG:** BI1356 high dose

## Key facts

- **NCT ID:** NCT01342484
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342484, "Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01342484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*